Niels Thue Olsen1, Ole De Backer2, Hans G H Thyregod2, Niels Vejlstrup2, Henning Bundgaard2, Lars Søndergaard2, Nikolaj Ihlemann2. 1. From the Department of Cardiology (N.T.O., O.D.B., N.V., H.B., L.S., N.I.), Department of Cardiothoracic Surgery (H.G.H.T.), Rigshospitalet, Copenhagen, Denmark. niels.thue.olsen.01@regionh.dk. 2. From the Department of Cardiology (N.T.O., O.D.B., N.V., H.B., L.S., N.I.), Department of Cardiothoracic Surgery (H.G.H.T.), Rigshospitalet, Copenhagen, Denmark.
Abstract
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an advancing mode of treatment for inoperable or high-risk patients with aortic stenosis. Prosthetic valve endocarditis (PVE) after TAVI is a serious complication, but only limited data exist on its incidence, outcome, and procedural risk factors. METHODS AND RESULTS: Observational single-center study of 509 consecutive patients treated with a transcatheter implanted self-expandable aortic valve prosthesis (Medtronic CoreValve). We identified 18 patients diagnosed with TAVI-PVE during a median follow-up period of 1.4 years (interquartile range, 0.5-2.5 years; longest follow-up was 6.3 years). TAVI-PVE was most frequent in the first year after implantation (first-year incidence, 3.1% [confidence interval, 1.4%-4.8%]); the overall annualized rate was 2.1% per patient-year (confidence interval, 1.2%-3.3%). Seventeen patients (94%) were treated conservatively and 1 with surgery. Four patients (22%) died from endocarditis or complications to treatment, 2 of those (11%) during initial hospitalization for PVE. An increased risk of TAVI-PVE was seen in patients with low implanted valve position (hazard ratio, 2.8 [1.1-7.2]), moderate or worse postprocedural paravalvular regurgitation (hazard ratio, 4.0 [1.5-11]), implantation of >1 prosthesis (hazard ratio, 5.2 [1.5-18]), and any vascular complication (hazard ratio, 3.8 [1.5-9.8]). CONCLUSIONS: TAVI-PVE occurred at a slightly higher rate than reported for surgically implanted valves. Conservative treatment was associated with an acceptable outcome. Suboptimal valve deployment and vascular complications were associated with an increased risk of TAVI-PVE.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an advancing mode of treatment for inoperable or high-risk patients with aortic stenosis. Prosthetic valve endocarditis (PVE) after TAVI is a serious complication, but only limited data exist on its incidence, outcome, and procedural risk factors. METHODS AND RESULTS: Observational single-center study of 509 consecutive patients treated with a transcatheter implanted self-expandable aortic valve prosthesis (Medtronic CoreValve). We identified 18 patients diagnosed with TAVI-PVE during a median follow-up period of 1.4 years (interquartile range, 0.5-2.5 years; longest follow-up was 6.3 years). TAVI-PVE was most frequent in the first year after implantation (first-year incidence, 3.1% [confidence interval, 1.4%-4.8%]); the overall annualized rate was 2.1% per patient-year (confidence interval, 1.2%-3.3%). Seventeen patients (94%) were treated conservatively and 1 with surgery. Four patients (22%) died from endocarditis or complications to treatment, 2 of those (11%) during initial hospitalization for PVE. An increased risk of TAVI-PVE was seen in patients with low implanted valve position (hazard ratio, 2.8 [1.1-7.2]), moderate or worse postprocedural paravalvular regurgitation (hazard ratio, 4.0 [1.5-11]), implantation of >1 prosthesis (hazard ratio, 5.2 [1.5-18]), and any vascular complication (hazard ratio, 3.8 [1.5-9.8]). CONCLUSIONS: TAVI-PVE occurred at a slightly higher rate than reported for surgically implanted valves. Conservative treatment was associated with an acceptable outcome. Suboptimal valve deployment and vascular complications were associated with an increased risk of TAVI-PVE.
Authors: J Ambrosioni; M Hernandez-Meneses; A Téllez; J Pericàs; C Falces; J M Tolosana; B Vidal; M Almela; E Quintana; J Llopis; A Moreno; José M Miro Journal: Curr Infect Dis Rep Date: 2017-05 Impact factor: 3.725
Authors: Khalil Ahmad; Kaj Erik Klaaborg; Vibeke Hjortdal; Bjarne Linde Nørgaard; Christian Juhl Terkelsen; Kaare Jensen; Evald Høj Christiansen; Kim Allan Terp; Gratien Andersen; Steen Hvitfeldt; Henning Rud Andersen Journal: J Thorac Dis Date: 2016-10 Impact factor: 2.895
Authors: Kiyoko Takemiya; Xinghai Ning; Wonewoo Seo; Xiaojian Wang; Rafi Mohammad; Giji Joseph; Jane S Titterington; Colleen S Kraft; Jonathan A Nye; Niren Murthy; Mark M Goodman; W Robert Taylor Journal: JACC Cardiovasc Imaging Date: 2018-04-18
Authors: Anthony J Buckley; Richard Tanner; Brian Armstrong; Saber Hassan; Barbara Moran; Jamie Byrne; Susan Groarke; Ronan Margey; Ivan P Casserly Journal: Ir J Med Sci Date: 2022-05-03 Impact factor: 2.089
Authors: Karol Zbroński; Zenon Huczek; Piotr Scisło; Janusz Kochman; Krzysztof J Filipiak; Grzegorz Opolski Journal: Postepy Kardiol Interwencyjnej Date: 2016-11-17 Impact factor: 1.426